5751 - 5775 of 6422 Results
Title
Year
-
OPENTitle: What the VaP? The meaning of “vascular parkinsonism”Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 94Issue #:Start Page: 132End Page: 134Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.12.008Citation Count: 7
-
OPENTitle: Olfaction, cholinergic basal forebrain degeneration, and cognition in early Parkinson diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 90Issue #:Start Page: 27End Page: 32Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.07.024Citation Count: 17
-
OPENTitle: Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriersJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 91Issue #:Start Page: 1End Page: 8Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.08.008Citation Count: 10
-
OPENTitle: Exploratory analysis of the genetics of impulse control disorders in Parkinson's disease using genetic risk scoresJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 74End Page: 77Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.003Best OA location URL: https://hal.archives-ouvertes.fr/hal-03298502Citation Count: 8
-
OPENTitle: Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patientsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 25End Page: 31Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.012Best OA location URL: http://www.prd-journal.com/article/S1353802021001450/pdfCitation Count: 19
-
OPENTitle: Plasma NfL, clinical subtypes and motor progression in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 87Issue #:Start Page: 41End Page: 47Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.016Citation Count: 45
-
OPENTitle: Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 83Issue #:Start Page: 79End Page: 85Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.024Best OA location URL: http://www.prd-journal.com/article/S135380202100016X/pdfCitation Count: 66
-
OPENTitle: White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 85Issue #:Start Page: 95End Page: 101Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.02.031Citation Count: 14
-
OPENTitle: Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI databaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 34End Page: 37Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.03.007Best OA location URL: https://repositorio.uca.edu.ar/handle/123456789/11625Citation Count: 12
-
OPENTitle: Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 82Issue #:Start Page: 133End Page: 137Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.002Best OA location URL: http://www.prd-journal.com/article/S1353802020309007/pdfCitation Count: 5
-
OPENTitle: Special Issue on new therapeutic approaches to Parkinson diseaseJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 208Issue #:Start Page: 108998End Page: 108998Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.108998Citation Count: 5
-
OPENTitle: Preserved motor memory in Parkinson's diseaseJournal Name: NeuropsychologiaPublisher: Elsevier BVVol: 167Issue #:Start Page: 108161End Page: 108161Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuropsychologia.2022.108161Citation Count: 13
-
OPENTitle: Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse modelJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 218Issue #:Start Page: 109213End Page: 109213Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.109213Best OA location URL: https://doi.org/10.1016/j.neuropharm.2022.109213Citation Count: 9
-
OPENTitle: Additive Effect of Dopaminergic Medication on Gait Under Single and Dual-Tasking Is Greater Than of Deep Brain Stimulation in Advanced Parkinson Disease With Long-Duration Deep Brain StimulationJournal Name: Neuromodulation: Technology at the Neural InterfacePublisher: Elsevier BVVol: 26Issue #: 2Start Page: 364End Page: 373Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurom.2022.01.015Citation Count: 4
-
OPENTitle: Critical considerations for the development of potency tests for therapeutic applications of mesenchymal stromal cell-derived small extracellular vesiclesJournal Name: CytotherapyPublisher: Elsevier BVVol: 23Issue #: 5Start Page: 373End Page: 380Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.jcyt.2021.01.001Best OA location URL: http://hdl.handle.net/11380/1251814Citation Count: 182
-
OPENTitle: Are hedge funds' charitable donations strategic?Journal Name: Journal of Corporate FinancePublisher: Elsevier BVVol: 66Issue #:Start Page: 101842End Page: 101842Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.jcorpfin.2020.101842Citation Count: 12
-
OPENTitle: Comparison of manual and automated measures of walking speed: Distance and pace matterJournal Name: Experimental GerontologyPublisher: Elsevier BVVol: 170Issue #:Start Page: 111987End Page: 111987Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.exger.2022.111987Best OA location URL: https://doi.org/10.1016/j.exger.2022.111987Citation Count: 3
-
OPENTitle: Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned ratJournal Name: European Journal of PharmacologyPublisher: Elsevier BVVol: 929Issue #:Start Page: 175090End Page: 175090Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ejphar.2022.175090Best OA location URL: https://doi.org/10.1016/j.ejphar.2022.175090Citation Count: 10
-
OPENTitle: Persistent depressive symptoms are associated with frontal regional atrophy in patients with Alzheimer's diseaseJournal Name: International Journal of Geriatric PsychiatryPublisher: WileyVol: 38Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/gps.5858Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/11217758Citation Count: 8
-
OPENTitle: Caregiving concerns and clinical characteristics across neurodegenerative and cerebrovascular disorders in the Ontario neurodegenerative disease research initiativeJournal Name: International Journal of Geriatric PsychiatryPublisher: WileyVol: 37Issue #: 6Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/gps.5727Citation Count: 8
-
OPENTitle: A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 MutationJournal Name: Clinical Pharmacology & TherapeuticsPublisher: WileyVol: 110Issue #: 2Start Page: 508End Page: 518Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/cpt.2277Citation Count: 13
-
OPENTitle: A Collaboration for Guiding the Rational Design of Multielement Solid CatalystsJournal Name: Angewandte Chemie International EditionPublisher: WileyVol: 62Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/anie.202216327Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/anie.202216327Citation Count: 0
-
OPENTitle: A Collaboration for Guiding the Rational Design of Multielement Solid CatalystsJournal Name: Angewandte ChemiePublisher: WileyVol: 135Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/ange.202216327Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ange.202216327Citation Count: 0
-
OPENTitle: Description of a European memory clinic cohort undergoing amyloid‐PET: The AMYPAD Diagnostic and Patient Management StudyJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 19Issue #: 3Start Page: 844End Page: 856Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/alz.12696Best OA location URL: https://pub.dzne.de/search?p=id:%22DZNE-2022-01312%22Citation Count: 12
-
OPENTitle: Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivityJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 19Issue #: 3Start Page: 956End Page: 966Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/alz.12697Best OA location URL: https://doi.org/10.1002/alz.12697Citation Count: 47